Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA ... Read More
Britannia Pharmaceuticals’ apomorphine shows promise in Phase 3 TOLEDO trial for Parkinson’s disease
Britannia Pharmaceuticals, a subsidiary of the British pharma group, has announced successful Phase 3 results for its APO-go/MOVAPO (apomorphine) subcutaneous infusion, marking a significant advancement ... Read More